Teladoc Adds Remote Monitoring to Solo as Telehealth Platforms Absorb More Hospital Work

Teladoc moves beyond video visits into hospital operations

Teladoc Health added contactless remote vital-sign monitoring and an ambient AI scribe to Solo, its virtual-care platform for hospitals. The AI scribe is available now to selected customers; contactless monitoring enters private preview and launches broadly in December 2026.

The expansion matters because Solo now competes as an operational layer for hospitals rather than a telehealth endpoint. The platform ingests data from EHRs, wall-mounted and mobile cameras, and tablets to support e-consults, virtual nursing, patient observation, and care-team analytics. That positions it against multiple categories: video-visit platforms like Amwell, virtual-nursing tools, ambient-documentation vendors, and remote patient monitoring point products.

Health systems should assess whether Teladoc can replace that stack or whether private-preview features create integration and maturity risk. Require evidence on clinical accuracy, false-alert rates, documentation quality, security controls, and EHR interoperability before budgeting for deployment. A consolidated vendor reduces contract overhead but concentrates technical and clinical risk.

General Medicine raises $120 million to build a cross-category marketplace

General Medicine raised a $120 million Series B led by Andreessen Horowitz, with participation from Matrix, VXI Capital, Eli Lilly, Mercy Health through Granger Management, and BoxGroup. Total funding reaches $152 million.

The company operates an online marketplace listing more than 2,900 products and services spanning prescriptions, laboratory testing, telehealth, specialist e-consults, and selected in-person care. It displays insurance and cash-pay pricing, allowing consumers to compare and purchase across categories. General Medicine plans to add imaging and more outpatient procedures.

The model competes with Amazon One Medical, Amazon Pharmacy, digital clinics, health-system consumer portals, and specialty platforms that control only one care category. For employers, health plans, and health systems, the development increases pressure to provide transparent, cross-category digital access rather than isolated telehealth benefits.

The channel-conflict risk is clear: a marketplace that controls patient discovery, pricing, referrals, and fulfillment could disintermediate provider organizations and incumbent benefits vendors. Buyers should evaluate whether their current digital front door can match the breadth, pricing transparency, and user experience of a third-party marketplace—or whether they need to partner with one.

Grindr acquires PurposeMed for up to $320 million

Grindr agreed to acquire PurposeMed, the parent company of Canadian PrEP telehealth provider Freddie, for $250 million upfront—$190 million in cash and $60 million in stock—with up to $70 million in performance-based payments. The transaction is expected to close in the fourth quarter of 2026.

Grindr plans to launch Grindr Health, initially offering PrEP access, testing, care, and medication delivery through Freddie's telehealth and pharmacy infrastructure. The company said it may add erectile-dysfunction treatments and GLP-1 medications.

This is a distribution and data-integration play, not simply a telehealth acquisition. Grindr brings an existing consumer audience; PurposeMed provides the clinical and pharmacy infrastructure. The move places Grindr against sexual-health telehealth companies, digital pharmacies, PrEP providers, and broader platforms such as Ro, Hims & Hers, Nurx, and Planned Parenthood-affiliated services.

Key diligence issues for enterprise buyers evaluating similar partnerships: consent for health-data use, pharmacy and prescribing controls, clinical governance, state and national regulatory coverage, and whether the consumer platform can maintain appropriate separation between engagement data and protected health information.

98point6 shifts from service provider to software vendor

Telehealth company 98point6 is transitioning from directly providing telehealth services to licensing its software to healthcare providers. The company raised almost $31 million, partly through borrowing, to support the shift.

Its software includes an AI-driven digital clinic, a clinician console for appointments, and patient-care tools that providers can use with their own care teams. This model competes more directly with Amwell, Teladoc's enterprise platform, EHR-native virtual-care tools, and white-label digital-clinic vendors.

Provider organizations gain more control over clinical staffing, branding, and workflows than with a fully outsourced telehealth service. However, buyers also assume greater responsibility for clinician coverage, medical liability, escalation protocols, AI oversight, and service-level performance. The trade-off is operational control for operational accountability.

What to watch

Platform consolidation is accelerating. Teladoc is adding monitoring and documentation to Solo, while General Medicine is combining telehealth with labs, medications, and in-person services. The shift reduces the number of vendors health systems need but increases the risk concentration and switching costs.

Distribution is now a strategic asset. Grindr's PurposeMed deal shows that an existing consumer audience can be as valuable as the underlying telehealth technology. Buyers should evaluate whether their own platforms can compete on patient access or whether they need to partner with companies that already own attention.

Software licensing shifts responsibility to providers. 98point6's model may lower vendor-service dependence but requires buyers to staff, operate, and govern the platform. Assess whether your organization has the clinical and technical capacity to run a licensed telehealth platform or whether a managed service remains the lower-risk choice.